|
- Telehealth for a healthy, handsome you | Hims
Hims is a 100% online platform with over 1 million subscribers that connects patients to licensed healthcare professionals in all 50 states We offer support for weight loss, hair regrowth, mental health, and skincare
- Novo Nordisk halts Wegovy sales on Hims Hers, claiming deceptive . . .
Shares of Hims Hers plunged more than $20, or roughly 31%, to $44 10 following Novo Nordisk's announcement Hims Hers did not immediately respond to a request for comment
- Novo Nordisk ends Wegovy deal with Hims Hers - CNBC
Novo Nordisk said Hims Hers has "failed to adhere to the law which prohibits mass sales of compounded drugs" under the "false guise" of personalization
- My Account – Hims, Inc.
We offer a variety of options to help you log into your account Options include traditional username and password, Google ID, or Apple ID Please follow the appropriate steps below based on your preferred login method App Access the Hims or Hers app on your mobile device Locate and tap the "Log in" button at the bottom of the screen If yo
- Hims Stock Crashes After Novo Yanks Deal Over Wegovy Knockoffs . . .
Hims stock had been on a run since the company announced the deal with Novo Shares jumped 23% on April 29 after the companies announced the collaboration Shares jumped 23% on April 29 after the
- Hims Hers: Devastating GLP-1 News Could Shatter Growth Narrative
Hims Hers Health (NYSE:HIMS) entered 2025 firing on all cylinders: first-quarter revenue more than doubled to $586 million, net income surged to $49 5 million, and operating cash flow touched $
- Hims Inc. - Investor relations
Hims Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health We believe how you feel in your body and mind transforms how you show up in life
- Novo Nordisk ends collaboration with Hims Hers for discounted weight . . .
Hims Hers' CEO Andrew Dudum said in a statement shared on X that the platform intends to continue to provide Wegovy for patients "We are disappointed to see Novo Nordisk management misleading the public In recent weeks, Novo Nordisk’s commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients
|
|
|